Page 65 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Designing miRNA ONTs for cardiometabolic pandemics

double-stranded RNA in Caenorhabditis elegans. Nature. 13. Anwar S, Mir F, Yokota T. Enhancing the effectiveness of
1998;391(6669):806-811. oligonucleotide therapeutics using Cell-penetrating peptide
conjugation, chemical modification, and carrier-based
doi: 10.1038/35888
delivery strategies. Pharmaceutics. 2023;15(4):1130.
2. Seyhan AA. Trials and tribulations of MicroRNA
therapeutics. Int J Mol Sci. 2024;25(3):1469. doi: 10.3390/pharmaceutics15041130
doi: 10.3390/ijms25031469 14. Khvorova A, Watts JK. The chemical evolution of
oligonucleotide therapies of clinical utility. Nat Biotechnol.
3. Hofman CR, Corey DR. Targeting RNA with synthetic 2017;35(3):238-248.
oligonucleotides: Clinical success invites new challenges.
Cell Chem Biol. 2024;31(1):125-138. doi: 10.1038/nbt.3765
15. Egli M, Schlegel MK, Manoharan M. Acyclic (S)-glycol
doi: 10.1016/j.chembiol.2023.09.005
nucleic acid (S-GNA) modification of siRNAs improves
4. Nappi F. Non-coding RNA-targeted therapy: A state-of-the- the safety of RNAi therapeutics while maintaining potency.
art review. Int J Mol Sci. 2024;25(7):3630. RNA. 2023;29(4):402-414.
doi: 10.3390/ijms25073630 doi: 10.1261/rna.079526.122
5. Dixon SJ, Stockwell BR. Identifying druggable disease- 16. Puri S, Mazza M, Roy G, et al. Evolution of nanomedicine
modifying gene products. Curr Opin Chem Biol. 2009;13(5- formulations for targeted delivery and controlled release.
6):549-555. Adv Drug Deliv Rev. 2023;200:114962.
doi: 10.1016/j.cbpa.2009.08.003 doi: 10.1016/j.addr.2023.114962
6. Takakusa H, Iwazaki N, Nishikawa M, Yoshida T, Obika S, 17. Penchovsky R, Georgieva AV, Dyakova V, Traykovska M,
Inoue T. Drug metabolism and pharmacokinetics of antisense Pavlova N. Antisense and functional nucleic acids in rational
oligonucleotide therapeutics: Typical profiles, evaluation drug development. Antibiotics (Basel). 2024;13(3):221.
approaches, and points to consider compared with small
molecule drugs. Nucleic Acid Ther. 2023;33(2):83-94. doi: 10.3390/antibiotics13030221
doi: 10.1089/nat.2022.0054 18. Brown CR, Gupta S, Qin J, et al. Investigating the
pharmacodynamic durability of GalNAc-siRNA conjugates.
7. Ranasinghe P, Addison ML, Dear JW, Webb DJ. Small Nucleic Acids Res. 2020;48(21):11827-11844.
interfering RNA: Discovery, pharmacology and clinical
development-An introductory review. Br J Pharmacol. doi: 10.1093/nar/gkaa670
2023;180(21):2697-2720. 19. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of
doi: 10.1111/bph.15972 MicroRNA biogenesis, mechanisms of actions, and
circulation. Front Endocrinol (Lausanne). 2018;9:402.
8. Friedrich M, Aigner A. Therapeutic siRNA: State-of-the-art
and future perspectives. BioDrugs. 2022;36(5):549-571. doi: 10.3389/fendo.2018.00402
doi: 10.1007/s40259-022-00549-3 20. Yedavilli S, Singh AD, Singh D, Samal R. Nano-messengers
of the heart: Promising theranostic candidates for
9. Egli M, Manoharan M. Chemistry, structure and function cardiovascular maladies. Front Physiol. 2022;13:895322.
of approved oligonucleotide therapeutics. Nucleic Acids Res.
2023;51(6):2529-2573. doi: 10.3389/fphys.2022.895322
doi: 10.1093/nar/gkad067 21. Henning RJ. Cardiovascular exosomes and MicroRNAs
in cardiovascular physiology and pathophysiology.
10. Kulkarni JA, Witzigmann D, Thomson SB, et al. The current J Cardiovasc Transl Res. 2021;14(2):195-212.
landscape of nucleic acid therapeutics. Nat Nanotechnol.
2021;16(6):630-643. doi: 10.1007/s12265-020-10040-5
doi: 10.1038/s41565-021-00898-0 22. Li C, Ni YQ, Xu H, et al. Roles and mechanisms of exosomal
non-coding RNAs in human health and diseases. Signal
11. Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. Transduct Target Ther. 2021;6(1):383.
2023 FDA TIDES (peptides and oligonucleotides) harvest.
Pharmaceuticals (Basel). 2024;17(2):243. doi: 10.1038/s41392-021-00779-x
doi: 10.3390/ph17020243 23. Shu Z, Tan J, Miao Y, Zhang Q. The role of microvesicles
containing microRNAs in vascular endothelial dysfunction.
12. De la Torre BG, Albericio F. The pharmaceutical industry
in 2023: An analysis of FDA drug approvals from the J Cell Mol Med. 2019;23(12):7933-7945.
perspective of molecules. Molecules. 2024;29(3):585. doi: 10.1111/jcmm.14716
doi: 10.3390/molecules29030585 24. Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA:

Volume 7 Issue 3 (2024) 12 doi: 10.36922/itps.3025